A generic alternative indicated for bone health. Enhanced absorption of calcium through this therapy ensures metabolic stability and maintains optimal structural integrity.
Utilized to manage calcium levels in patients with kidney disease to address bone weakness and mitigate the risk of mineral imbalances.
Mechanism of Action
Alfacalcidol is converted by the liver into the active form of Vitamin D. It increases the absorption of calcium and phosphate from the gut, helping to strengthen bones and regulate parathyroid hormone levels.
Route of Administration
Oral
Onset Time
Days for initial effect
Duration
Days to weeks
Contraindications
Hypercalcemia, Vitamin D toxicity, Magnesium-containing stone risk, Hypersensitivity
Severe Adverse Events
Severe hypercalcemia, Kidney stones, Vessel calcification, Heart rhythm abnormalities, Severe kidney injury
Information for Alfacalcidol is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
